Article
Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.
Cancer chemotherapy and pharmacology - 1 Sept 2024
Cereja-Pantoja Karla Beatriz Cardias, de Brito Azevedo Tereza Cristina, Vinagre Lui Wallacy Morikawa Souza, de Moraes Francisco Cezar Aquino, da Costa Nunes Giovanna Gilioli, Monte Natasha, de Alcântara Angélica Leite, Cohen-Paes Amanda, Fernandes Marianne Rodrigues, Batista Dos Santos Sidney Emanuel, de Assumpção Paulo Pimentel, Ribeiro Dos Santos Ândrea Kely, Burbano Rommel Mario Rodríguez, Guerrero Raquel Cruz, Carracedo Ángel, Carneiro Dos Santos Ney Pereira
Abstract excerpt
Imatinib is the tyrosine kinase inhibitor used as the gold standard for the treatment of Chronic Myeloid Leukemia. However, about 30% of patients do not respond well to this therapy. Variants in drug administration, distribution, metabolism and excretion (ADME) genes play an important role in drug resistance especially in admixed populations. We investigated 129 patients diagnosed with Chronic Myeloid Leukemia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.